epidermolysis bullosa
DEBRA Research and Dermaliq Therapeutics collaborate to advance treatment for rare skin disorder
May 29, 2025Research and Development DEBRA Research, Dermaliq Therapeutics, Dermatology, epidermolysis bullosa, non-profit organisation, skin disorders
Global non-profit organisation, DEBRA Research, and clinical dermatology company, Dermaliq Therapeutics, have announced a collaboration to advance drug development for …
Promising interim Phase 3 data spurs epidermolysis bullosa trial expansion for Amryt
January 7, 2019Research and Development, Sales and Marketing Amryt, epidermolysis bullosa, pharma, rare disease
Rare disease firm Amryt has announced interim efficacy data for its epidermolysis bullosa (EB) therapy AP101, showing that things are …
Amicus pulls plug on rare skin disease drug after Phase 3 failure
September 14, 2017Research and Development Amicus, epidermolysis bullosa, pharma, pharmaceutical, trial failure
New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …
Latest content
Jennings becomes President of Beckman Coulter Diagnostics
October 19, 2026
Boyds expands Regulatory Affairs team to support growing demand
October 16, 2026
Sterling doubles ADC manufacturing capacity at Welsh facility
October 16, 2026
Femtosecond laser cuts lung tumour margin assessment time
October 15, 2026
